Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study
Gilead’s antibody-drug conjugate Trodelvy combined with Merck’s Keytruda reduced the risk of disease progression or death in a key study of an aggressive form of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
